Blaze Biosciences is more than halfway to a targeted $15 million in a Series B round to fund its Tumor Paint, a surgical tool that visually distinguishes solid tumor cells from healthy cells.
Founded in 2010, the Seattle, Wash.-based Blaze Biosciences has roped in about $8.1 million since opening the round in June, and the company has until Aug. 31, 2015, when the round is set to expire, to scrounge up the next $6.9 million.